Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Next Previous
Search
Trial Profile

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Abscess; Aspergillosis; Blastomycosis; Candidaemia; Coccidioidomycosis; Endocarditis; Histoplasmosis; Invasive candidiasis; Mediastinitis; Mucocutaneous candidiasis; Mycoses; Oesophagitis; Oropharyngeal candidiasis; Osteomyelitis; Vulvovaginal candidiasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FURI
  • Sponsors SCYNEXIS

    • Most Recent Events

    • 12 Mar 2025 According to a SCYNEXIS media release, The data from this trial will be presented at the ESCMID Global congress, April 11-15 2025 in Vienna, Austria.
    • 06 Nov 2024 According to a SCYNEXIS media release, clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3 2024
    • 28 Mar 2024 According to a SCYNEXIS media release, final study reports from FURI, CARES, SCYNERGIA, NATURE, and VANQUISH studies are anticipated to be delivered to GSK in the mid of 2024, which would trigger a $10 million development milestone payment to SCYNEXIS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top